Tumours

Pancreatic cancer
#Cancer research #iOnctura #Pancreatic cancer #Tumours

Breaking barriers in pancreatic cancer

World Pancreatic Cancer Day takes place on 21 November to raise awareness about pancreatic cancer, support patients and their families, and advocate for increased research and early detection of this deadly disease. iOnctura’s Chief Medical Officer Michael Lahn discusses how we can fight the disease by breaking the defensive wall… Read More

#Cancer Research #Exclusive Content

Antibodies
#Bio-Rad Laboratories #Cancer research #Circulating tumour cell enumeration #Tumours

Validated antibodies for rare cell and circulating tumour cell enumeration 

Bio-Rad Laboratories has launched validated antibodies for rare cell and circulating tumour cell (CTC) enumeration for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits.  The antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of… Read More

#Cancer Research #News

FDA approval
#FDA #Oncology #Regulatory #SpringWorks Therapeutics #Tumours

FDA approves first therapy for rare non-cancerous tumours

SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has become the first drug to be approved for desmoid tumours in the US, following the go-ahead from the US Food and Drug Administration (FDA). Desmoid tumours are non-cancerous but can be locally aggressive. Although surgical removal has historically been the treatment… Read More

#News #Regulatory

Cancer tumour
#Biotechnology #Cancer research #iOnctura #Tumours

New research highlights potential of combination cancer treatment 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.   Resistance to TGF‐β… Read More

#Cancer Research #News

handshake
#Acquisition #PARP inhibitors #Radiopharmaceuticals #Tumours

Ariceum Therapeutics expands pipeline with acquisition 

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.  The acquisition provides Ariceum with an… Read More

#News

Tumour microenvironment
#Absci #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Oncology #St John’s Cancer Institute #Tumours

Partners use AI to speed up development of cancer therapies

AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.   The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More

#Cancer Research #News

#Cancer research #Immune system #Immunotherapy #Oncology #Tumour biology #Tumours

Avoiding detection – the cancer cells evading the body’s natural defence

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study… Read More

#Cancer Research #Exclusive Content

Two scientists working in a research laboratory
#Antibody #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Merck #Mersana Therapeutics #Partnership #Tumours

Research partners hope to develop novel antibody-drug conjugates

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform… Read More

#Business & Investment #News

Testing acidity in the lab
#Cancer immunotherapy #Cancer research #Cancer treatment #Cytokines #Immunotherapy #Tumours

Acid discovery raises hopes of improved immunotherapies

The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a new study that could lead to a new generation of immunotherapy treatments.  Tumours have a more acidic environment (pH 6.5) than normal, healthy tissues (pH 7.2). New research has shown for the first time… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News

Wear it Pink
#Breast cancer #Breast Cancer Now #Cancer research #Chemotherapy #Chemotherapy-resistance #Drug discovery #Oncology #Tumours

Five breakthroughs advancing breast cancer therapies

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More

#Cancer Research #News #Trending News

#ESMO #European Society for Medical Oncology #Tumours

New treatment hope for patients with rare tumours

Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 by Professor Robin Jones, MD, Head of the Sarcoma Unit at… Read More

#News

#Cancer research #Immunotherapy #Oncology #Tumours

Immunotherapy challenges and tools for research 

Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy.  The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22… Read More

#Cancer Research #Editor's Choice #News #Opinion

Human liver
#Clinical trials #Liver disease #Oncology #Therapeutics #Tumours

First patient dosed in advanced liver cancer clinical trial 

MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).  What is OUTREACH-2?  OUTREACH-2 is a multi-centre,… Read More

#News #Trending News

Liver cancer
#Liver disease #Tumours

Dompé and Engitix tackle fibrosis and liver-associated solid tumours 

Dompé Farmaceutici has entered a strategic collaboration with and investment in Engitix as part of Engitix’s $54m Series A financing to support identification of new treatments against fibrosis and liver-associated solid tumours.  The agreement   Dompé will provide direct access to facilities, resources and expertise including its Exscalate structure-based drug design platform which can design… Read More

#News

#Biotechnology #Clinical trials #Drug development #Tumours

Avacta takes step to increase the tolerability of chemotherapies  

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.  The technology  Avacta’s chemistry is used to modify chemotherapy drugs to render them inactive… Read More

#News